Superior Planning, LLC’s Pacira BioSciences PCRX Stock Holding History

Superior Planning, LLC’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$752	Buy	+30	New	+$760	﹤0.01%	1817

Other funds holding PCRX

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $13B AUM 14.15% 1-Year Est. Return

Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Superior Planning, LLC's PCRX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Pacira BioSciences (PCRX) in Q3 2026: 30 shares worth $752. The stake represents ﹤0.01% of the portfolio and ranks #1817 among its holdings.

164 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

Superior Planning, LLC held 30 shares of Pacira BioSciences worth $752 as of Q3 2026.
Pacira BioSciences was a new Superior Planning, LLC position in Q3 2026.
Pacira BioSciences made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1817 holding.
164 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.